JP2018516931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516931A5 JP2018516931A5 JP2017562660A JP2017562660A JP2018516931A5 JP 2018516931 A5 JP2018516931 A5 JP 2018516931A5 JP 2017562660 A JP2017562660 A JP 2017562660A JP 2017562660 A JP2017562660 A JP 2017562660A JP 2018516931 A5 JP2018516931 A5 JP 2018516931A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- binding antibody
- administered
- functional fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 8
- 229960001838 canakinumab Drugs 0.000 claims 4
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 3
- 230000036772 blood pressure Effects 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 210000003423 ankle Anatomy 0.000 claims 2
- 229960002885 histidine Drugs 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 235000014304 histidine Nutrition 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 229960001855 mannitol Drugs 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 229940071643 prefilled syringe Drugs 0.000 claims 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 229950009116 mevastatin Drugs 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000037081 physical activity Effects 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170761P | 2015-06-04 | 2015-06-04 | |
| US62/170,761 | 2015-06-04 | ||
| PCT/IB2016/053242 WO2016193931A1 (en) | 2015-06-04 | 2016-06-02 | Use of il-1 beta binding antibodies to treat peripheral arterial disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018516931A JP2018516931A (ja) | 2018-06-28 |
| JP2018516931A5 true JP2018516931A5 (enExample) | 2018-08-16 |
Family
ID=56132984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562660A Pending JP2018516931A (ja) | 2015-06-04 | 2016-06-02 | 末梢動脈疾患を処置するためのｉｌ−１ベータ結合抗体の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20210198356A1 (enExample) |
| EP (1) | EP3303388A1 (enExample) |
| JP (1) | JP2018516931A (enExample) |
| AU (1) | AU2016272900A1 (enExample) |
| CA (1) | CA2988055A1 (enExample) |
| WO (1) | WO2016193931A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2575853A (en) * | 2018-07-25 | 2020-01-29 | Robert Wotherspoon Hugh | IL-1ß binding antibody |
| BR112021004999A2 (pt) | 2018-09-17 | 2021-06-08 | Yungjin Pharm. Co., Ltd. | composto e método de inibição de cdk7 em um sujeito |
| AU2019406840A1 (en) * | 2018-12-21 | 2021-06-03 | Novartis Ag | Use of IL-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| US10000565B2 (en) | 2012-11-16 | 2018-06-19 | Novartis Ag | Use of IL-1 β binding antibodies for treating peripheral arterial disease |
-
2016
- 2016-06-02 AU AU2016272900A patent/AU2016272900A1/en not_active Abandoned
- 2016-06-02 JP JP2017562660A patent/JP2018516931A/ja active Pending
- 2016-06-02 WO PCT/IB2016/053242 patent/WO2016193931A1/en not_active Ceased
- 2016-06-02 CA CA2988055A patent/CA2988055A1/en not_active Abandoned
- 2016-06-02 EP EP16729638.3A patent/EP3303388A1/en not_active Withdrawn
-
2021
- 2021-03-17 US US17/204,622 patent/US20210198356A1/en not_active Abandoned
-
2023
- 2023-03-28 US US18/191,471 patent/US20230265182A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2549724C (en) | Use of treprostinil to treat and prevent ischemic lesions | |
| Dahlöf et al. | Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension) | |
| Jafarinia et al. | Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial | |
| KR101186029B1 (ko) | 신경병증성 당뇨병성 족부 궤양을 치료하기 위한트레프로스티닐의 용도 | |
| JP2015187125A5 (enExample) | ||
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| JP2016502526A5 (enExample) | ||
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| JP2017528427A5 (enExample) | ||
| RU2012110592A (ru) | Соединения и способ снижения мочевой кислоты | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2017132791A (ja) | 組み合わせ組成物 | |
| JP2018531605A5 (enExample) | ||
| JP2017501154A5 (enExample) | ||
| RU2008135360A (ru) | Композиции и способы лечения пациентов с сердечно-сосудистыми, церебрально-васкулярными и другими сосудистыми заболеваниями | |
| JP2018516931A5 (enExample) | ||
| JP2019533715A5 (enExample) | ||
| RU2523412C1 (ru) | Способ лечения больных облитерирующими заболеваниям и артерий нижних конечностей | |
| RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
| JPWO2019237054A5 (enExample) | ||
| Henderson et al. | Chronic inflammatory demyelinating polyradiculoneuropathy and severe peripheral oedema: a renal explanation | |
| Hall et al. | Vitamin B12 and coordination exercises for combined degeneration of the spinal cord in pernicious anemia | |
| RU2025131205A (ru) | Производные имидазотриазина в качестве модуляторов il-17 | |
| RU2025131206A (ru) | Производные имидазотриазина в качестве модуляторов il-17 | |
| RU2013148539A (ru) | Алиспоривир для лечения инфекции вируса гепатита с |